Article
Oncology
Pengjie Yu, Shengmao Zhu, Yushuang Luo, Ganggang Li, Yongqiang Pu, Baojia Cai, Chengwu Zhang
Summary: This study explores the application value of circulating tumor cells (CTCs) and circulating free DNA (cfDNA) from peripheral blood in the prognosis of advanced gastric cancer (AGC). The results show that the concentration of peripheral blood CTCs and cfDNA is correlated with the efficacy and prognosis of neoadjuvant chemotherapy.
JOURNAL OF ONCOLOGY
(2022)
Review
Oncology
Juan Sun, Xianze Wang, Zimu Zhang, Ziyang Zeng, Siwen Ouyang, Weiming Kang
Summary: Research on predicting the sensitivity of NACT for gastric cancer spans multiple aspects including biomarkers, inflammatory indicators, and imaging assessments. While numerous studies have been conducted on biomarkers, a unified conclusion has not yet been reached. Inflammatory indicators have been shown to be associated with the survival and prognosis of patients undergoing NACT, and imaging assessments such as CT, MRI, and PET may offer unique advantages in early screening for NACT-sensitive patients through careful integration and optimization.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Crystal S. Denlinger, Kristina A. Matkowskyj, Mary F. Mulcahy
Summary: The treatment landscape for gastric and esophageal cancers has been significantly influenced by pivotal trials evaluating immune checkpoint inhibitors (ICIs), leading to changes in NCCN Guidelines. New treatment options such as trastuzumab-deruxtecan (T-DXd) and nivolumab are now recommended for certain patient populations.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Review
Oncology
M. Usman Ahmad, Christopher Javadi, George A. Poultsides
Summary: Neoadjuvant and/or perioperative therapy has emerged as a treatment tool to improve patient selection and locoregional control for resectable proximal gastric, gastroesophageal junction, and distal esophageal cancer. Treatment recommendations differ based on histologic type and tumor location. Neoadjuvant chemoradiation with concurrent taxane- or fluoropyrimidine-based chemotherapy has shown efficacy for both adenocarcinoma and squamous cell carcinoma of the distal esophagus and gastroesophageal junction.
Editorial Material
Oncology
Shogo Kumagai, Shohei Koyama, Kohei Shitara
Summary: Studies have shown that immunochemotherapy is the preferred treatment for advanced esophageal cancer. Chen et al. and Carrol et al. conducted exploratory analysis of the JUPITER-06 and LUD2015-005 trials, respectively, and identified biomarkers for predicting treatment response through immunogenomic analysis. These findings can potentially improve patient stratification in advanced esophageal cancer.
Review
Oncology
Ming Han, Mengyuan Zhang, Mei Qi, Yue Zhou, Fulong Li, Shengquan Fang
Summary: Gastric cancer is a common malignancy worldwide, and exosomes play an important role in its development by transporting bioactive substances. Circular RNA, a type of non-coding RNA with a specific structure, is widely present in exosomes and has a critical role in regulating various physiological processes in gastric cancer.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Yang Li, Zhenxing Wang, Rao Fu, Shuang Wang, Tingting Zhang, Xudong Tian, Dawei Yang
Summary: Detection of CTCs using NE-FISH could be helpful in the diagnosis of EC. The proportion of CTCs with chromosome 7 triploidy was related to distant metastasis and TNM stage. Patients with CTCs ≥ 3 had short OS, while distant metastasis was an independent factor indicating a poor prognosis for patients with EC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Gabriela M. Almeida, Carla Pereira, Ji-Hyeon Park, Carolina Lemos, Sofia Campelos, Irene Gullo, Diana Martins, Gilza Goncalves, Dina Leitao, Joao Luis Neto, Ana Andre, Clara Borges, Daniela Almeida, Hyuk-Joon Lee, Seong-Ho Kong, Woo Ho Kim, Fatima Carneiro, Raquel Almeida, Han-Kwang Yang, Carla Oliveira
Summary: The study identified high CD44v6 membranous expression as a potential predictive marker for response to conventional treatment in gastric cancer, supporting the selection of patients with high CD44v6-expressing tumors for chemotherapy in addition to surgery. The findings could lead to better stratification of patients for treatment and potentially improve overall survival.
Article
Biophysics
Syed Harris Hussain, Cesar S. Huertas, Arnan Mitchell, Anne-Laure Deman, Emmanuelle Laurenceau
Summary: Analysis of circulating tumor cells (CTCs) and their associated biomarkers can provide valuable information for lung and prostate cancer, aiding in early detection and personalized treatment selection. Biosensors offer an elegant alternative to conventional methods for real-time, multiplexed analysis of cancer biomarkers at lower concentrations.
BIOSENSORS & BIOELECTRONICS
(2022)
Editorial Material
Medicine, General & Internal
David H. Ilson
Summary: Esophageal cancer is a major cause of cancer-related illness and death worldwide, often presenting with locally advanced or metastatic disease due to lack of effective screening or early detection. Esophageal squamous-cell carcinoma is the most common histologic type globally, especially in high-incidence areas like East Asia, while adenocarcinoma dominates in the West. Surgical outcomes for esophageal squamous-cell cancer patients in 1980 highlighted the significant challenge in treating esophageal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Wojciech Jelski, Barbara Mroczko
Summary: Gastric cancer is a highly malignant tumor with poor prognosis, and early diagnosis and effective monitoring are crucial for reducing disease burden and mortality. Blood-based biomarker assays have the potential for early-stage detection of gastric cancer. However, the currently used tumor marker assays have limitations in sensitivity and specificity. In recent years, multiple markers have been identified and tested for their clinical relevance in gastric cancer management. This review summarizes the available literature on various blood-based biomarkers and discusses their potential for early diagnosis and accurate prediction of therapeutic approaches.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Huiling Wang, Yufei Xu, Fengli Zuo, Junzhi Liu, Jiqiao Yang
Summary: This article provides a systematic summary and analysis of immunotherapy-based combination therapies for esophageal cancer (EC), highlighting the clinical advantages and various treatment options, particularly the use of PD-1 monoclonal antibodies.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Claire Tonry, Adam Russell-Hallinan, Claire McCune, Patrick Collier, Mark Harbinson, Lana Dixon, Chris J. Watson
Summary: Cancer therapeutics-related cardiac dysfunction (CTRCD) is a major cause of disease and death in cancer survivors. The clinical management of CTRCD is hindered by a lack of sensitive diagnostic and prognostic strategies. Circulating molecular markers could potentially be useful in the diagnosis and management of CTRCD. Researchers have been searching for new biomarkers and hope that these markers can also guide the development of cardio-protective therapies.
CARDIOVASCULAR RESEARCH
(2023)
Article
Oncology
Xiaoyuan Ma, Eric Pierce, Harsh Anand, Natalie Aviles, Paul Kunk, Negin Alemazkoor
Summary: This study uses data from 150 patients with stage-IV gastric and esophageal cancers to train machine learning models that predict whether patients would benefit from palliative chemotherapy (PC) in terms of increased survival duration at early stages of treatment. The findings show that machine learning can accurately predict whether a patient will benefit from PC at the time of diagnosis. More accurate predictions can be obtained after only two cycles of PC. The results of this study are promising in terms of improving quality of life for end-of-life patients and optimizing systemic therapy for overall survival benefits.
Review
Oncology
Caroline Fong, Edwina Johnston, Naureen Starling
Summary: Gastric cancer requires a multimodality approach to achieve optimal curative rates. Preferences for neoadjuvant and adjuvant approaches vary across the globe, but a multimodal approach provides clear survival benefits compared to surgery alone. However, the completion rates of adjuvant therapy are low, highlighting the need for patient selection optimization and individualized treatment strategies.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Surgery
Maximilian Kloft, Jessica E. Ruisch, Gayatri Raghuram, Jake Emmerson, Matthew Nankivell, David Cunningham, William H. Allum, Ruth E. Langley, Heike I. Grabsch
Summary: This study analyzed the relationship between negative lymph node size and overall survival in esophageal cancer patients. It found that large negative lymph node size is associated with better survival and may serve as a new prognostic biomarker. Further studies are needed to confirm these findings and explore the underlying biological mechanisms.
Editorial Material
Oncology
Joseph P. Doyle, Pranav H. Patel, Sophie L. F. Doran, Long R. Jiao, David Cunningham, David Nicol, Vasileios K. Mavroeidis, William H. Allum, Asif M. Chaudry, Ricky H. Bhogal, Sacheen Kumar
ANNALS OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Hematology
Bambang Atmaja, Thomas Millard, Andrew Wotherspoon, Ayoma D. Attygalle, David Cunningham, Bhupinder Sharma
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Susanna Slater, Annette Bryant, Hsiang-Chi Chen, Ruwaida Begum, Isma Rana, Maria Aresu, Clare Peckitt, Oleg Zhitkov, Retchel Lazaro-Alcausi, Victoria Borja, Rachel Powell, David Lowery, Michael Hubank, Thereasa Rich, Gayathri Anandappa, Ian Chau, Naureen Starling, David Cunningham
Summary: This study aims to determine whether a de-escalation strategy using ctDNA to guide adjuvant chemotherapy is as effective as standard of care chemotherapy in patients with resected colorectal cancer. The primary endpoint is the difference in disease-free survival at 3 years between the trial arms. The study has the potential to reduce unnecessary chemotherapy and associated toxicity.
Article
Surgery
Michal Kawka, Tamara M. H. Gall, Fiona Hand, Scarlet Nazarian, David Cunningham, David Nicol, Long R. Jiao
Summary: This study retrospectively analyzed 60 cases of robotic pancreatoduodenectomy (RPD) and found a significant decrease in operative time after 21 RPD cases. This suggests that technical proficiency in RPD improves after a certain number of procedures have been performed.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Article
Medicine, General & Internal
Mairead G. McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sharmila Sothi, Alan Anthoney, Christopher Bell, Alkesh Patel, Jamie B. Oughton, David A. Cairns, Wasat Mansoor, Angela Lamarca, Richard A. Hubner, Juan W. Valle
Summary: This study compared the efficacy of liposomal irinotecan/5-FU/folinic acid and docetaxel in the treatment of PD-EP-NEC as second-line therapy. The results showed that liposomal irinotecan/5-FU/folinic acid achieved a 6-month progression-free survival rate of 29.6%, while docetaxel did not meet the primary endpoint. Liposomal irinotecan/5-FU/folinic acid demonstrated manageable toxicity and maintained quality of life.
Meeting Abstract
Oncology
J. Mencel, F. Turkes, L. Barber, B. Challoner, M. Buzzetti, A. Tran, H. Chen, N. McCafferty, A. Woolston, R. Crux, I. Rana, J. Thomas, V. Borja, R. Begum, E. Johnston, N. Fotiadis, M. Terlizzo, S. Rao, I. Chau, D. Cunningham, M. Gerlinger, N. Starling
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Do-Youn Oh, Maria Alsina Maqueda, David I. Quinn, Peter J. O'Dwyer, Ian Chau, Sun Young Kim, Ignacio Duran, Daniel Castellano, Jordan Berlin, Begona Mellado, Stephen K. Williamson, Keun-Wook Lee, Francisca Marti, Paul Mathew, Muhammad Wasif Saif, Ding Wang, Elizabeth Chong, Jacqueline Hilger-Rolfe, James P. Dean, Hendrik-Tobias Arkenau
Summary: This study evaluated the safety and efficacy of Ibrutinib combined with companion drugs for RCC, GC, and CRC, but did not observe clinically significant increases in efficacy compared to historical controls.
Article
Oncology
Jonathan L. Moore, Michael Green, Aida Santaolalla, Harriet Deere, Richard P. T. Evans, Mona Elshafie, Anita Lavery, Damian T. McManus, Andrew McGuigan, Rosalie Douglas, Joanne Horne, Robert Walker, Hira Mir, Monica Terlizzo, Sivesh K. Kamarajah, Mieke Van Hemelrijck, Nick Maisey, Ailsa Sita-Lumsden, Sarah Ngan, Mark Kelly, Cara R. Baker, Sacheen Kumar, Jesper Lagergren, William H. Allum, James A. Gossage, Ewen A. Griffiths, Heike I. Grabsch, Richard C. Turkington, Tim J. Underwood, Elizabeth C. Smyth, Rebecca C. Fitzgerald, David Cunningham, Andrew R. Davies
Summary: This study aimed to evaluate the influence of lymph node (LN) regression on survival after surgery for esophageal adenocarcinoma. The results showed that patients with complete LN regression, partial LN regression, or negative LNs had a lower mortality rate compared to those with poor/no LN regression.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Marwan G. Fakih, Lisa Salvatore, Taito Esaki, Dominik P. Modest, David P. Lopez-Bravo, Julien Taieb, Michalis V. Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
Summary: In this study, the combination of KRAS G12C inhibitor sotorasib and EGFR inhibitor panitumumab showed longer progression-free survival compared to standard treatment in patients with chemorefractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Meeting Abstract
Oncology
Neil McCafferty, Caroline Fong, Louise J. Barber, Andrew Woolston, Dimitrios Kleftogiannis, Taqia Rana, Susan Cromarty, Shannon Kidd, Ruwaida Begum, Ian Chau, Naureen Starling, David Cunningham, Marco Gerlinger
Meeting Abstract
Oncology
Marco Gerlinger, Anderley Gordon, Louise J. Barber, Georgios Laliotis, Avani Athauda, Benjamin Challoner, Andrew Woolston, Sonia Mansukhani, Matt Dunstan, Nikoletta Petrou, Komel Khabra, Retchel Lazaro-Alcausi, Richard Crux, Victoria Borja, Ruwaida Begum, Isma Rana, Charuta Palsuledesai, Meenakshi Malhotra, Minetta Liu, Adham Jurdi, Shruti Sharma, Sheela Rao, Sacheen Kumar, David Cunningham, Ian Chau, Naureen Starling, M. Asif Chaudry
Article
Engineering, Biomedical
Edward W. Johnston, Jodie Basso, Francisca Silva, Arafat Haris, Robin L. Jones, Nasir Khan, Helen Lawrence, Jakob Mathiszig-Lee, James McCall, David C. Cunningham, Nicos Fotiadis
Summary: The purpose of this study was to evaluate the feasibility, safety, and accuracy of robotic radiofrequency ablation (RFA) for pulmonary metastases compared to conventional freehand placement. The study found that robotic RFA was technically successful with high accuracy and fewer manipulations, leading to improved safety and reduced complications compared to freehand placement.
INTERNATIONAL JOURNAL OF COMPUTER ASSISTED RADIOLOGY AND SURGERY
(2023)
Article
Oncology
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell, Clare Peckitt, Caroline Fong, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Fribbens, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham, Nicola Valeri
Summary: This study identified miR-148a-3p as a potential biomarker for trastuzumab-based therapy in HER2-positive oesophago-gastric cancer patients. The results showed that the expression level of miR-148a-3p is associated with patient survival and progression rates.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Benjamin R. Challoner, Andrew Woolston, David Lau, Marta Buzzetti, Caroline Fong, Louise J. Barber, Gayathri Anandappa, Richard Crux, Ioannis Assiotis, Kerry Fenwick, Ruwaida Begum, Dipa Begum, Tom Lund, Nanna Sivamanoharan, Harold B. Sansano, Melissa Domingo-Arada, Amina Tran, Hardev Pandha, David Church, Bryony Eccles, Richard Ellis, Stephen Falk, Mark Hill, Daniel Krell, Nirupa Murugaesu, Luke Nolan, Vanessa Potter, Mark Saunders, Kai-Keen Shiu, Sebastian Guettler, James L. Alexander, Hector Lazare-Iglesias, James Kinross, Jamie Murphy, Katharina von Loga, David Cunningham, Ian Chau, Naureen Starling, Juan Ruiz-Banobre, Tony Dhillon, Marco Gerlinger
Summary: MMRd CRCs have high mutation burdens and pervasive ITH, but driver mutations show a clear hierarchy. Immune evasion (IE) drivers are mainly subclonal and show parallel evolution. IE drivers and T cell infiltrates coevolve. PD-L1 expression correlates with T cell density but is associated with loss of CDX2 expression, leading to a higher recurrence risk in MMRd CRCs.
JOURNAL OF PATHOLOGY
(2023)